Eli Lilly and Company
893 S Delaware St
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We also have been committed to investing in our employees – through competitive salaries, training and development, health, and the opportunity to do good. The pharmaceutical industry is a complex, rapidly changing environment and we’re looking for people who are determined to make life better for people around the world. Visit https://careers.lilly.com for more information.
Stock Symbol: LLY
Stock Exchange: NYSE
We discover life-changing medicines. We commit to diversity and inclusion. We volunteer millions of hours. We make life better. We are Lilly.
2322 articles with Eli Lilly and Company
Predictive biomarkers can reduce unnecessary treatment and adverse effects unlike chemotherapy and targeted therapies which may cause toxic effects.
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease
Tau Morphomer™ is the focus of a partnership with Eli Lilly and Company
Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study
Data from OVERCOME shed new light on migraine stigma by examining attitudes through the eyes of people who have not been diagnosed with migraine
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine
Results showed that treatment with Emgality, when compared to placebo, resulted in lower levels of migraine-related disability and fewer restrictions on daily activities that are limited by migraine, such as relationships with family and friends, leisure time, productivity, concentration, energy and fatigue
Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine
Eli Lilly and Company (NYSE: LLY) announced the upcoming presentation of data highlighting inconsistent and sub-optimal treatment patterns that people living with migraine experience across the U.S. healthcare landscape, specifically related to where they receive care.
At Kite, Shaw will focus on turning around the company's flagship CAR-T treatment Yescarta, as well as focus on the development of other cancer-targeting cell therapies.
7/12/2019Biotech and pharma companies strengthen their leadership teams with new appointments.
New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache
Eli Lilly and Company announced that the New England Journal of Medicine published positive Phase 3 study results of Emgality® for the treatment of episodic cluster headache.
111 Building "Fourth Sales Channel" to Support Pharmaceutical Companies and Accelerate Drug Distribution Outside of Hospitals
111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, announced that on July 5, 2019 it extended its strategic partnership with Eli Lilly and Company (NYSE: LLY) ("Lilly"), a global healthcare leader, by becoming a key distributor for the latter's market-leading product "Cialis."
Vendors in the cancer biologics market have significantly increased investments for the development of cancer treating biologic molecules.
Lilly Announces Upcoming Presentation of New Data Indicating Rise in Opioid Use for Migraine Treatment
Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of data indicating rising rates of opioid use for the treatment of migraine based on results from the OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) study
Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2019 financial results on Tuesday, July 30, 2019.
The increase in smoking and the consumption of tobacco products have resulted in increased incidences of laryngeal cancer.
As fireworks illuminate the night skies across the United States this weekend in celebration of Independence Day, BioSpace takes a look at some of the highlights of the pharma industry from the first half of 2019 and earlier that provides millions of patients with the independence of health.
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, presented the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma with sintilimab, co-developed with Eli Lilly and Company and key data from six other clinical studies were presented at the 55th Annual Meeting of the American Society of Clinical Oncology by oral presentation and posters.
According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!
Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.
NMPA Accepts New Drug Application for IBI301, a Biosimilar Product Candidate of Rituximab (MabThera/Rituxan)
Innovent Biologics, Inc. and Eli Lilly and Company jointly announced that the National Medical Products Administration has accepted its new drug application for IBI301, a co-developed biosimilar product candidate of rituximab.
Lilly's AWARD-11 trial studying higher investigational doses of Trulicity® (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes
Eli Lilly and Company's trial studying higher investigational doses of Trulicity® met its primary efficacy endpoint of superiority, significantly reducing A1C from baseline in people with type 2 diabetes, compared to once-weekly Trulicity 1.5 mg after 36 weeks.
The U.S. Food and Drug Administration has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced.